Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SoFi Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280.46 (market cap $39.89B), while SoFi Technologies Inc trades at $18.31 (market cap $24.09B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and SoFi Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SOFI | |
|---|---|---|
Market Cap | $39.89B | $24.09B |
Sector | Health | Financials |
52-Week High | $491.22 | $32.21 |
52-Week Low | $278.09 | $15.15 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SoFi Technologies (SOFI) trades at $18.78, up 0.86% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $3.61B in 2025, though net income dipped to $481M. The company expanded its ETF lineup with SFYI and acquired AI investing agent Composer, driving positive media coverage. Support sits at $18, resistance at $19.
Outlook: SoFi's bank charter and digital expansion offer growth, but high P/E (41.73) and volatile cash flows pose risks. Analyst consensus target is $22.43 (17% upside), yet mixed ratings reflect execution concerns. Key risks include interest rate sensitivity and competitive fintech pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
